NCT03346668View on ClinicalTrials.gov

Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 28, 2016

Primary Completion Date

October 11, 2021

Study Completion Date

October 11, 2021

Conditions
Scarring AlopeciaFrontal Fibrosing AlopeciaLichen PlanopilarisCentral Centrifugal Cicatricial AlopeciaCentral Centrifugal Scarring Alopecia
Interventions
DRUG

Topical gabapentin

topical gabapentin 6% solution

Trial Locations (1)

55455

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT03346668 - Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia | Biotech Hunter | Biotech Hunter